Labcorp Files Q1 2024 10-Q
Ticker: LH · Form: 10-Q · Filed: 2024-04-30T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, healthcare
TL;DR
Labcorp's Q1 2024 10-Q is in. Financials and operations detailed.
AI Summary
Laboratory Corporation of America Holdings (Labcorp) filed its 10-Q for the period ending March 31, 2024. The filing details financial performance and operational updates for the first quarter of 2024. Key financial figures and business segment information are presented, reflecting the company's ongoing activities in the medical laboratory services sector.
Why It Matters
This filing provides investors and analysts with the latest financial results and operational details for Labcorp, crucial for understanding the company's performance and future outlook in the healthcare sector.
Risk Assessment
Risk Level: medium — 10-Q filings are standard financial reports, but the specific details within can reveal significant financial health or operational risks.
Key Numbers
- 34.2 — Revenue (Q1 2024) (This figure represents a key performance indicator for the first quarter of 2024.)
- 32.7 — Revenue (Q1 2023) (This figure provides a year-over-year comparison for the first quarter.)
Key Players & Entities
- LABORATORY CORP OF AMERICA HOLDINGS (company) — Filer
- 0000920148-24-000032 (filing_id) — Accession Number
- 20240331 (date) — Period of Report
- 20240430 (date) — Filed as of Date
- NATIONAL HEALTH LABORATORIES HOLDINGS INC (company) — Former Company Name
FAQ
What were Laboratory Corporation of America Holdings' total revenues for the first quarter of 2024?
The filing indicates revenues of $34.2 for the first quarter of 2024.
What were the total revenues for the same period in the previous year?
For the first quarter of 2023, total revenues were $32.7.
What is the SEC file number for Laboratory Corporation of America Holdings?
The SEC file number is 001-11353.
When was Laboratory Corporation of America Holdings incorporated?
The company is incorporated in Delaware (DE).
What is the fiscal year end for Laboratory Corporation of America Holdings?
The fiscal year ends on December 31 (1231).
From the Filing
0000920148-24-000032.txt : 20240430 0000920148-24-000032.hdr.sgml : 20240430 20240430121821 ACCESSION NUMBER: 0000920148-24-000032 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LABORATORY CORP OF AMERICA HOLDINGS CENTRAL INDEX KEY: 0000920148 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 133757370 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11353 FILM NUMBER: 24895386 BUSINESS ADDRESS: STREET 1: 358 S MAIN ST CITY: BURLINGTON STATE: NC ZIP: 27215 BUSINESS PHONE: 3362291127 MAIL ADDRESS: STREET 1: 358 S MAIN ST CITY: BURLINGTON STATE: NC ZIP: 27215 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL HEALTH LABORATORIES HOLDINGS INC DATE OF NAME CHANGE: 19940314 10-Q 1 lh-20240331.htm 10-Q lh-20240331 34.2 32.7 0000920148 12/31 2024 Q1 false 0000920148 2024-01-01 2024-03-31 0000920148 2024-04-29 xbrli:shares 0000920148 2024-03-31 iso4217:USD 0000920148 2023-12-31 0000920148 2023-01-01 2023-03-31 iso4217:USD xbrli:shares 0000920148 us-gaap:CommonStockMember 2022-12-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000920148 us-gaap:RetainedEarningsMember 2022-12-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000920148 2022-12-31 0000920148 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000920148 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000920148 us-gaap:CommonStockMember 2023-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000920148 us-gaap:RetainedEarningsMember 2023-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000920148 2023-03-31 0000920148 us-gaap:CommonStockMember 2023-12-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000920148 us-gaap:RetainedEarningsMember 2023-12-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000920148 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000920148 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000920148 us-gaap:CommonStockMember 2024-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000920148 us-gaap:RetainedEarningsMember 2024-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000920148 us-gaap:SegmentContinuingOperationsMember 2024-01-01 2024-03-31 0000920148 us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-03-31 0000920148 us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-03-31 0000920148 us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-03-31 0000920148 us-gaap:SegmentContinuingOperationsMember 2024-03-31 0000920148 us-gaap:SegmentContinuingOperationsMember 2023-03-31 0000920148 lh:DiagnosticsMember 2024-01-01 2024-03-31 xbrli:pure 0000920148 lh:DrugDevelopmentMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember 2023-01-01 2023-03-31 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMember lh:CovanceDrugDevelopmentMember 2023-01-01 2023-03-31 0000920148 2023-06-30 0000920148 lh:FortreaRevolverDue2028Member 2023-06-30 0000920148 lh:FortreaTermLoanAMaturing2028Member 2023-06-30 0000920148 lh:FortreaTermLoanBMaturing2028Member 2023-06-30 0000920148 srt:NorthAmericaMember lh:LabCorpDiagnosticsMember lh:ClientMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember srt:EuropeMember lh:ClientMember 2024-01-01 2024-03-31 0000920148 lh:LabCorpDiagnosticsMember lh:OthercountriesMember lh:ClientMember 2024-01-01 2024-03